Your browser doesn't support javascript.
loading
ETS1 Suppresses Tumorigenesis of Human Breast Cancer via Trans-Activation of Canonical Tumor Suppressor Genes.
Kim, Gi-Cheon; Lee, Choong-Gu; Verma, Ravi; Rudra, Dipayan; Kim, Taemook; Kang, Keunsoo; Nam, Jong Hee; Kim, Young; Im, Sin-Hyeog; Kwon, Ho-Keun.
Afiliação
  • Kim GC; Department of Microbiology and Immunology, Yonsei University College of Medicine, Seoul, South Korea.
  • Lee CG; Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, South Korea.
  • Verma R; Natural Product Informatics Research Center, Korea Institute of Science and Technology (KIST), Gangneung Institute of Natural Products, Gangneung, South Korea.
  • Rudra D; Academy of Immunology and Microbiology (AIM), Institute for Basic Science (IBS), Pohang, South Korea.
  • Kim T; Academy of Immunology and Microbiology (AIM), Institute for Basic Science (IBS), Pohang, South Korea.
  • Kang K; Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, South Korea.
  • Nam JH; Department of Microbiology, College of Natural Sciences, Dankook University, Cheonan, South Korea.
  • Kim Y; Department of Pathology, Chonnam National University Medical School, Gwangju, South Korea.
  • Im SH; Department of Oral Pathology, School of Dentistry, Chonnam National University, Gwangju, South Korea.
  • Kwon HK; Academy of Immunology and Microbiology (AIM), Institute for Basic Science (IBS), Pohang, South Korea.
Front Oncol ; 10: 642, 2020.
Article em En | MEDLINE | ID: mdl-32477936
ABSTRACT
ETS1 has shown dichotomous roles as an oncogene and a tumor suppressor gene in diverse cancers, but its functionality in breast cancer tumorigenesis still remains unclear. We utilized the Cancer Genome Atlas (TCGA) database to analyze comprehensive functions of ETS1 in human breast cancer (BRCA) patients by investigating its expression patterns and methylation status in relation to clinical prognosis. ETS1 expression was significantly diminished by hyper-methylation of the ETS1 promoter region in specimens from BRCA patients compared to a healthy control group. Moreover, ETS1 high BRCA patients showed better prognosis and longer survival compared to ETS1 low BRCA patients. Consistent with clinical evidence, comparative transcriptome analysis combined with CRISPR/Cas9 or shRNA based perturbation of ETS1 expression revealed direct as well as indirect mechanisms of ETS1 that hinder tumorigenesis of BRCA cells. Taken together, our study enlightens a novel function of ETS1 as a tumor suppressor in breast cancer cells.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Coréia do Sul

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Coréia do Sul